Search
My Stocks
SGX
Google
Yahoo
News
TradingView
IX BIOPHARMA LTD. (42C)
SGD 0.121
+1.65% +0.00
Portfolio
Watchlist
Divs
Anns
Trans
Notes
Articles
All
Financial
Buy Back
Insider Trading
2024-03-01
General Announcement::Termination Of Wafermine Licensing Agreement
2024-02-05
Financial Statements and Related Announcement::Half Yearly Results
2023-12-01
Employee Stock Option/ Share Scheme::Grant of Share Awards Pursuant to iX Performance Share Plan
2023-11-17
General Announcement::Notice Of Termination Of Wafermine Licensing Agreement
2023-11-14
General Announcement::Change of Address of Share Registrar and Place Where Register of Members and Index Is Kept
2023-11-10
General Announcement::Minutes of Annual General Meeting Held on 13 October 2023
2023-10-13
REPL::Annual General Meeting::Voluntary
2023-10-11
General Announcement::Responses to Questions from the Securities Investors Association (Singapore)
2023-10-06
General Announcement::Questions & Answers Provided by iX Biopharma Ltd for Annual General Meeting on 13 October 2023
2023-10-04
General Announcement::Corrigenda - Corporate Governance Reports 2022 and 2023
2023-09-29
General Announcement::Press Release - iX Biopharma Introduces MeltMed in USA
2023-09-25
Annual Reports and Related Documents::
2023-09-25
Annual General Meeting::Voluntary
2023-08-21
Financial Statements and Related Announcement::Full Yearly Results
2023-08-15
General Announcement::Press Release - iX Biopharma Develops Sublingual Interferon
2023-07-24
General Announcement::Proposed Issuance of Convertible Bonds of An Aggregate Principal Amount of S$2,000,000 - Completion
2023-07-17
General Announcement::Proposed Issuance of Convertible Bonds of S$2,000,000 - Receipt of Listing and Quotation Notice
2023-07-03
General Announcement::Proposed Issuance of Convertible Bonds of an Aggregate Principal Amount of S$2,000,000
2023-02-10
Financial Statements and Related Announcement::Half Yearly Results
2023-02-09
General Announcement::Press Release: iX Biopharma Successfully Completes Phase 1 Sublingual Dexmedetomidine Clinical Study
2022-12-02
General Announcement::Reconstitution of the Board Committees
2022-11-11
General Announcement::Minutes of Annual General Meeting Held on 14 October 2022
2022-11-07
Change - Announcement of Appointment::Appointment of Independent Non-Executive Director
2022-11-07
General Announcement::Appointment of Independent Non-Executive Director and Re-Constitution of the Board
2022-11-04
Employee Stock Option/ Share Scheme::Grant of Share Awards Pursuant to iX Performance Share Plan
2022-10-21
General Announcement::IX BIOPHARMA WINS BEST CBD SUBLINGUAL EDIBLE AWARD
2022-10-14
REPL::Annual General Meeting::Voluntary
2022-10-07
REPL::Annual General Meeting::Voluntary
2022-09-22
Annual General Meeting::Voluntary
2022-09-22
Annual Reports and Related Documents::
2022-09-22
Change - Announcement of Cessation::Retirement of Independent and Non-Executive Director - Mr Low Weng Keong
2022-08-28
General Announcement::Press Release - Launch of Sublingual Dexmedetomidine Programme
2022-08-22
Financial Statements and Related Announcement::Full Yearly Results
2022-07-21
Placements::PROPOSED PLACEMENT OF 13,710,000 NEW ORDINARY SHARES - ALLOTMENT AND ISSUE OF SUBSCRIPTION SHARES
2022-07-19
Placements::PROPOSED PLACEMENT OF 13,710,000 NEW ORDINARY SHARES - RECEIPT OF LISTING AND QUOTATION NOTICE
2022-07-18
General Announcement::DRUG DEVELOPMENT UPDATES FOR WAFERMINE AND WAFESIL
2022-07-15
Change - Announcement of Cessation::Cessation of Director of Corporate Affairs & General Manager - Yee Chia Hsing
2022-07-12
Placements::PROPOSED PLACEMENT OF 13,710,000 NEW ORDINARY SHARES
2022-07-07
REPL::Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)::Notice of Cessation as Substantial Shareholder - Jaspal Singh Narulla
2022-07-06
Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)::Notice of Cessation as Substantial Shareholder - Jaspal Singh Narulla
2022-02-11
Financial Statements and Related Announcement::Half Yearly Results
2022-02-11
General Announcement::Press Release: iX Biopharma Records 1H22 Net Profit of S$3.66M
2022-02-11
Request for Trading Halt::Request for Trading Halt
2022-02-11
Request for Lifting of Trading Halt::Request for Lifting Of Trading Halt
2022-02-11
General Announcement::Request for Lifting of Trading Halt - Sponsor's Statement
2022-02-11
Request for Lifting of Trading Halt::Request for Lifting of Trading Halt
2022-02-04
General Announcement::Change of Secretaries
2022-01-28
Change - Announcement of Appointment::APPOINTMENT OF NON-EXECUTIVE INDEPENDENT DIRECTOR
2022-01-28
General Announcement::APPOINTMENT OF NON-EXECUTIVE INDEPENDENT DIRECTOR & CHANGE IN COMPOSITION OF BOARD & ITS COMMITTEES
2022-01-20
General Announcement::Phillip Securities Presentation - January 2022
«
Previous
1
2
3
4
5
»
Next
© 2025 Dividends.sg /
More Countries